RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough

NCT ID: NCT02396706

Last Updated: 2015-09-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 181 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2015-06-30

Brief Summary

Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough

Conditions

Acute Cough

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Ivy Leaves Cough Liquid

Ivy Leaves Cough Liquid

Group Type: ACTIVE_COMPARATOR

Ivy Leaves Cough Liquid

Intervention Type: DRUG

Placebo

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Ivy Leaves Cough Liquid

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Acute cough with symptoms lasting 2-3 days prior to treatment

2. Men or women of any ethnic origin

3. Age 18 to 75 years

4. Subjects who are able to understand and are willing to comply to trial instructions

5. Having given written informed consent

6. Satisfactory health except for the cough as determined by the investigator based on medical history and physical examination

7. CS score of at least 50 mm on a 100 mm VAS at V1

8. Acute BSS of at least 10 points at V1

9. VCD score of at least 2 points at V1

Exclusion Criteria

1. Allergic bronchial asthma, bronchial hyperreactivity, chronic bronchitis, other chronic or inherited lung disease

2. History of hypersensitivity to any excipient of the applied drugs

3. History of drug hypersensitivity, asthma, urticaria, or other severe allergic diathesis as well as current hay fever

4. History of chronic gastritis or peptic ulcers

5. Any gastrointestinal complaints within 7 days before V1

6. Participation in a clinical trial within 30 days prior to the treatment phase of this study or concomitantly

7. Treatment with corticoids, beta-2 agonists (e.g. salbutamol, fenoterol), expectorants, theophylline, antitussives, anaesthetics, acetylsalicylic acid (e.g. aspirin) or other non-steroidal anti-inflammatory drugs, leukotriene inhibitors, angiotensin-converting enzyme (ACE) inhibitors, antiviral drugs or antibiotics, antihistamines, immunosuppressants, isoprenaline, atropine, sodium cromoglycate or homeopathic drugs against common cold within 7 days before V1

8. Drug or alcohol abuse in the opinion of the investigator

9. Pregnant or nursing (lactating) women

10. Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception.

11. Subjects with significant diseases, defined as a disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the trial or a disease which may influence the results of the trial or the subject's ability to participate in the trial; includes subjects with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease.

12. Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Engelhard Arzneimittel GmbH & Co.KG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Axel Schaefer

Role: PRINCIPAL_INVESTIGATOR

Medizentrum Essen-Borbeck

Locations

Medizentrum Essen-Borbeck

Essen, , Germany

Countries

Germany

Other Identifiers

EA-14-01-077

Identifier Type: -

Identifier Source: org_study_id